A Multicenter, Randomized Trial of YINYI? Polymer-Free Paclitaxel - Eluting Stent vs. Polymer Sirolimus - Eluting Stent in the Emergency PCI


Principal Investigator: Leifeng Wang, MD, Beijing Chao-yang Hospital
Sponsor: Liaoning Biomedical Materials R&D Center Co., Ltd.


YINYI? Polymer-free Paclitaxel-Eluting Coronary Stent
Polymer-based Sirolimus-Eluting Coronary Stent (Firebird 2, Partner, Excel and others)


1584 patients in all
YINYI polymer-free PES vs. Durable polymer SES = 3:1

Primary Endpoint

Ischemic driven TLR (i-TLR) at 1 year

Secondary Endpoints

1.PCI success rate (separately record the facts of device performance and lesion condition)
2.Emergency intervention efficiency (separately record the time from Onset to Admission, Admission to Cath lab, Cath lab to Open artery, Admission to Open artery), analysis the time efficiency and influencing factors
3.Definite/Probable stent thrombosis according to ARC (acute, sub-acute, late)
4.Make detailed record to the doses and adjust points of DAPT, especially pay attention to the stent thrombosis in those patients who have stopped the DAPT due to special cases
5.MACE at 30d, 6m, 1yr
6.All death and cardiac death at 30d, 6m, 1yr
7.Composite safety endpoint (cardiac death, myocardial infarction, stent thrombosis) at 30d, 6m, 1yr, especially record the composite safety including stent thrombosis and the reason of earlier interruption of antiplatelet drugs caused by patient's disease at each follow-up point
8.TVR and TVF at 30d, 6m, 1yr. TVF = Target-vessel related death, re-MI (Q wave and non-Q wave), TLR (Re-PCI or CABG)

Clinical Results

Coming soon…

上海十一选五最新开奖结果 手机打字赚钱靠谱吗 福利彩票如何看中奖 内蒙古快三平台下载 股票配资平台哪个安全靠谱认准大牛时代 河南快三基本上势分部图 云南时时彩最快开奖 钢铁板块股票分析 美女感受急速赛车漂移 吉林股票配资公司招聘 重庆幸运农场什么时候开盘 金管家期货配资真实吗 喜乐彩怎样玩 格力电器股票分析报告 送现金的棋牌游戏 广东11选五中奖规则 快乐10分口诀任四5倍中奖有多少钱